SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% – Should You Sell?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares were down 5.5% during trading on Thursday . The company traded as low as $3.89 and last traded at $3.8850. Approximately 1,619,858 shares were traded during trading, a decline of 90% from the average daily volume of 15,726,965 shares. The stock had previously closed at $4.11.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, SELLAS Life Sciences Group presently has an average rating of “Hold” and a consensus target price of $7.00.

SELLAS Life Sciences Group Stock Performance

The business has a fifty day simple moving average of $2.39 and a 200 day simple moving average of $2.03. The stock has a market cap of $534.87 million, a price-to-earnings ratio of -13.41 and a beta of 2.26.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. On average, equities research analysts anticipate that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current fiscal year.

Insider Activity at SELLAS Life Sciences Group

In other news, Director Katherine Bach Kalin purchased 63,400 shares of the stock in a transaction dated Wednesday, November 19th. The stock was acquired at an average cost of $1.59 per share, for a total transaction of $100,806.00. Following the completion of the acquisition, the director directly owned 104,400 shares in the company, valued at $165,996. This represents a 154.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is currently owned by company insiders.

Institutional Trading of SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently bought and sold shares of the company. Axxcess Wealth Management LLC purchased a new stake in shares of SELLAS Life Sciences Group in the third quarter valued at $26,000. BNP Paribas Financial Markets grew its holdings in SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after buying an additional 9,299 shares during the period. Blair William & Co. IL purchased a new stake in SELLAS Life Sciences Group in the 2nd quarter valued at about $35,000. ProShare Advisors LLC acquired a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at about $43,000. Finally, Sei Investments Co. purchased a new position in shares of SELLAS Life Sciences Group during the 3rd quarter worth about $43,000. 17.38% of the stock is owned by hedge funds and other institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.